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The purpose of the present study was to assess the differential intraocular pressure response 
(IOP) to dexamethasone (DEX) treatment at two dose levels (100 or 500 nM) in perfusion cultured 
Indian cadaveric eyes to investigate glucocorticoid (GC) responsiveness. In a human organ-cultured 
anterior segment (HOCAS) set-up, the eye pressure was monitored for every 24 h post DEX infusion 
(100 or 500 nM) or 0.1% ethanol treatment for 7 days after baseline stabilization. The expression 
of DEX-inducible proteins such as myocilin and fibronectin in HOCAS-TM tissues was assessed by 
immunostaining. Elevated IOP was observed in 6/16 eyes [Mean ± SEM (mΔIOP): 15.50 ± 1.96 mmHg; 
37.5% responders] and 3/15 eyes (Mean ± SEM mΔIOP: 10 ± 0.84 mmHg; 20% responders) in 100 nM 
and 500 nM dose groups respectively. Elevated IOP in GC responder eyes was substantiated with a 
significant increase in myocilin (11.8-fold; p = 0.0002) and fibronectin (eightfold; p = 0.04) expression 
as compared to vehicle-treated eyes by immunofluorescence analysis. This is the first study reporting 
the GC responsiveness in Indian cadaveric eyes. The observed GC response rate was comparable with 
the previous studies and hence, this model will enable us to investigate the relationship between 
differential gene expression and individual GC responsiveness in our population.
Glucocorticoids (GC) have been the mainstay for the management of inflammatory eye diseases due to its potent 
anti-inflammatory, anti-angiogenic and immune-modulatory  properties1. Chronic use of GC induces ocular 
hypertension (GC-OHT) and GC-induced glaucoma (GIG) in susceptible individuals (GC responders)2,3. It 
is reported that 40% of the patients in the general population showed an increased intraocular pressure (IOP) 
with topical dexamethasone use, of which, 6% are likely to develop  glaucoma2,4,5. More than 90% of the glau-
coma patients are GC responders which further complicates clinical management as a GC response can effect 
IOP control increasing the susceptibility of losing vision in these  patients3,6. Both GIG and primary open angle 
glaucoma (POAG) share similarities in clinical presentation such as an open angle, increased IOP, characteristic 
optic neuropathy and loss of peripheral  vision7,8. However, the molecular mechanisms for the pathogenesis of 
GIG are not completely  understood3.
The trabecular meshwork (TM) is an important component in the conventional aqueous humor outflow 
pathway which plays a crucial role in maintaining the IOP homeostasis. GCs are known to induce alterations in 
TM structure and function including inhibition of cell proliferation and  migration9, cytoskeletal rearrangement 
(formation of cross-linked actins (CLANs)10–12, increased TM cell and nuclear  size7, accumulation of excessive 
extracellular  matrix11,13, decreased  phagocytosis14 and alterations in cellular junctional  complexes15. These cellu-
lar, biochemical and morphological changes result in increased outflow resistance and decreased outflow facility.
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Several in vitro, in vivo and ex vivo models have been developed to understand the pathogenesis of GI-OHT/
GIG at a cellular and molecular  level16. Perfused organ-cultured anterior segment (OCAS) has been used as a 
standard ex vivo model to examine the aqueous outflow pathway in glaucoma research for nearly 30  years17–20. 
This model serves as an intermediate between in vitro and in vivo systems and offers unique opportunity to study 
the physiology, biochemistry and morphology of the outflow pathway for a number of days (up to 1 month) in 
viable  tissues19. In addition, the GC responder rate of perfusion cultured non-glaucomatous human eyes was 30% 
which is very close to the response rate observed in human  subjects2,10. However, such a high GC responsiveness 
rate was not reported by other  groups18.
To our knowledge, no studies have been reported to date in the Indian population. Therefore, the purpose of 
the present study was to utilize the human organ-cultured anterior segment (HOCAS) ex vivo model to investi-
gate the GC responsiveness of Indian cadaveric eyes to dexamethasone (DEX) treatment at two dose levels (100 
or 500 nM). This study identified 37.5% of eyes showed a GC response with the 100 nM dose of DEX and inter-
estingly, a 500 nM DEX dose resulted in a 20% response rate. No dose-dependent increase in the GC response 
rate was observed in the studied eyes despite of increasing the DEX dose to fivefold. The elevated IOP of the GC 
responder eyes was substantiated with a significant increase in mean fluorescence intensity of myocilin (11.8-fold; 
p = 0.0002) and fibronectin expression (eightfold; p = 0.04) as compared to vehicle-treated and non-responder 
eyes by immunofluorescence analysis. Thus, the HOCAS model provides a platform to investigate the molecular 
mechanisms contributing to differential responses in the TM to GCs and the heterogeneity of glucocorticoid 
receptor (GR) signaling both in health and diseased conditions.
Results
A total of 43 human donor eyes (7 paired; 29 single eyes) with the mean age of 73.0 ± 9.50 years were used for the 
present study and their demographic details are summarized in Supplementary Table S1. All anterior segments 
were cultured within 48 h of death (mean ± SD: 29.71 ± 14.89 h).
Differential IOP response to DEX treatment. Human eyes were perfusion cultured with either DEX 
or 0.1% ethanol (ETH) as vehicle control for 7 days as described  previously10,21. The DEX-induced elevated IOP 
was studied at two dose levels (100 nM and 500 nM) to check the dose-dependent response rate (RR). Out of 43 
eyes, 16 eyes received 100 nM DEX, 15 eyes received 500 nM DEX and 12 eyes received 0.1% ethanol (ETH) for 
7 days. Elevated IOP was observed in (6/16; RR = 37.5%) eyes in 100 nM dose group whereas in 500 nM dose 
group, 3/15 eyes showed a significant elevated IOP (RR = 20%).
A significant and progressive increase in IOP was observed in DEX-responder eyes after treatment with 
the mean Δ (± SEM) IOP of 15.5 ± 1.96 mmHg in 100 nM dose group and 10.0 ± 0.84 mmHg in 500 nM dose 
group. The mean ΔIOP in DEX-non-responder eyes was found to be 1.19 ± 0.54 mmHg and 1.32 ± 0.47 mmHg 
in 100 nM and 500 nM DEX respectively. The vehicle treated eyes remained stable throughout the study and the 
mean pressure was well below 5 mmHg (1.19 ± 0.46 mmHg). The DEX-treated responder eyes were statistically 
different from non-responder eyes and vehicle-treated eyes (p < 0.001) (Fig. 1a,b,c). In addition, the elevated IOP 
between 100 and 500 nM DEX-treated responder eyes were statistically significant (p = 0.04).
The mean (± SEM) basal outflow facility of total eyes (n = 43) was found to be 0.17 ± 0.01 µl/minute/mmHg at 
the perfusion rate of 2.5 µl/minute. In the DEX 100 nM dose group, the basal outflow facility of GC responder and 
GC non-responder eyes were 0.19 ± 0.04 and 0.16 ± 0.02 µl/minute/mmHg respectively; whereas in 500 nM dose 
group, the basal outflow facility of GC responder and GC non-responder eyes were 0.16 ± 0.01 and 0.16 ± 0.01 µl/
min/mmHg respectively. The basal outflow facility of ETH treated eyes was calculated to be 0.19 ± 0.01 µl/min/
mmHg. There was no significant difference found among three groups which further confirms that the observed 
elevated IOP in GC responder eyes was purely due to DEX treatment and not due to endogenous differences in 
the outflow facility and IOP of the studied eyes. The raw data of IOP and outflow facility of all the studied eyes 
are summarized in Supplementary Table S2A, 2B respectively.
Effect of DEX on morphology and tissue viability. A deposition of high extracellular debris was found 
in DEX-treated anterior segments as compared to vehicle-treated eyes (Fig. 2a). TUNEL assay revealed that the 
tissue viability was not affected by either DEX/ETH treatment (Fig. 2b).
DEX-induced myocilin and fibronectin expression in HOCAS-TM tissues. The effect of DEX on 
the expression of myocilin and fibronectin was investigated in TM tissues after HOCAS experiment by immu-
nofluorescence analysis and the representative images are shown in Fig. 3a,b. Interestingly, upon quantification 
a significant increase in mean fluorescence intensity of myocilin expression was found in GC responder eyes 
(11.8-fold) as compared to vehicle-treated eyes (p = 0.0002) and GC non-responder eyes (p = 0.0004) whereas 
fibronectin showed a eightfold increase in its expression (p = 0.04) (Fig. 3c). This clearly indicates that the ele-
vated IOP correlates with a significant increase in myocilin and fibronectin expression.
Discussion
The present study demonstrated the differential IOP response of perfused human cadaveric eyes to DEX treat-
ment at two dose levels (100 and 500 nM). The dose of 100 nM DEX was chosen based on the concentration of 
DEX found in the aqueous humor of the human eyes following topical administration of a single drop of 0.1% 
DEX  formulations22. The fivefold increase in DEX was chosen to explore any dose-dependent variations in IOP 
response and also in some in vitro studies, 500 nM dose was used to explore the gene /proteomic alterations in 
response to DEX treatment in cultured human TM  cells23–26.
3
Vol.:(0123456789)
Scientific Reports |          (2021) 11:605  | https://doi.org/10.1038/s41598-020-80112-8
www.nature.com/scientificreports/
Figure 1.  Effect of DEX on IOP. (a) The mean ± SEM of ∆IOP of ETH (vehicle control), DEX-treated responder 
and non-responder eyes were plotted over time. The eye pressure of the anterior segments in culture was acquired 
using Power Lab data acquisition system (AD Instruments, NSW, Australia) and analyzed using LabChart Pro 
software (ver.8.1) as described in detail in methods section. The basal IOP on day 0 (before DEX treatment) 
was set at 0 mmHg. In 100 nM dose group, treatment with DEX showed a significant elevated IOP in 6/16 eyes 
(Mean ± SEM—mΔIOP: 15.50 ± 1.96 mmHg; Response rate: 37.5%) whereas in 500 nM dose group, 3/15 eyes showed 
a very significant elevated IOP (Mean ± SEM—mΔIOP: 10 ± 0.84 mmHg; Response rate: 20%). ETH treated eyes 
showed mean ± SEM—mΔIOP of 0.92 ± 0.54 mmHg. Data were analyzed by unpaired 2-tailed Student’s t test on each 
treatment day. *p < 0.05; **p < 0.001; ***p < 0.0001; ****p < 0.00001. Frequency Plot of the (b) IOP data and (c) Outflow 
facility data. The m∆IOP and outflow facility of ETH treated, DEX-responder and DEX-non-responder groups were 
plotted for both 100 and 500 nM dose groups. The m∆IOP was increased after DEX treatment in responder eyes as 
compared to non-responder and ETH-treated eyes whereas outflow facility was decreased significantly after DEX 
treatment (100 and 500 nM) in responder group as compared to non-responder and ETH-treated groups.
Figure 2.  Effect of DEX on Morphology and Tissue viability. (a) Histology of Anterior Segment received (i, iv) 
0.1% ETH, (ii, v) 100 nM DEX and (iii, vi) 500 nM DEX treatment for 7 days. High deposition of extracellular 
debris was found in DEX-treated eyes (indicated in black color arrow) (v, vi) as compared to vehicle-treated 
eyes (iv). (b) Representative images showing TUNEL positivity in (i) positive control (DNAase I treated), (ii) 
0.1% ETH treated eyes, (iii) 100 nM DEX (iv) 500 nM DEX treated eyes and (v) Graph showing the percentage 
of TUNEL positive cells in ETH (n = 6), 100 nM DEX (n = 6) and 500 nM DEX-treated eyes (n = 6). No 
significant toxicity was observed after DEX treatment. The TUNEL positivity is indicated in red color arrow. 
TM-Trabecular meshwork; SC-Schlemm’s canal and CB- Ciliary body.
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The change in IOP in response to DEX treatment (“ΔIOP”, defined as the maximum IOP after treatment 
minus the baseline IOP) was determined as a positive response for all studied eyes. The “GC responder eyes” 
were defined according to the criteria described earlier with a positive ΔIOP ≥ 5 mmHg above baseline IOP fol-
lowing DEX treatment and the “GC- non-responder eyes” are those with their ΔIOP ≤ 5 mmHg above baseline 
 IOP10. Based on these criteria, the GC responsive eyes of the present study were found to be 37.5% at 100 nM 
dose. Most of the eyes were found to be moderate responders (ΔIOP range: 8–15 mmHg). The observed GC 
response rate for 100 nM dose is comparable with the previous observation in perfusion cultured human  eyes10.
GC responsiveness mainly depends upon the potency, route of administration, dosage and duration of GC 
 exposure3. Interestingly, in our study by increasing the dose of DEX by fivefold (from 100 to 500 nM) did not 
show any dose-dependent increase in GC-response rate for the 500 nM group (20%) and their response rate was 
1.9-fold less as compared to 100 nM dose group (37.5%). The inability of higher dose to elicit a dose-dependent 
increase in 500 nM dose group could be due to the saturation effect of GC receptors which may be responsible 
for the observed progressive decline in IOP response in the present study (Fig. 1).
In this study, a 7 days treatment regimen was chosen to investigate the IOP response of the studied eyes to 
DEX because the observed lag time of high IOP was between 3 and 5 days. Therefore, a 7 days treatment regi-
men was sufficient to get a positive GC response in our studied eyes. In contrast, the previous study observed 
the lag time of high IOP after 5–6 days and hence the eyes needed longer exposure time of 10–15 days for DEX 
 treatment10. This could be due to variations in the flow rate used, as the present study utilized the flow rate of 
2.5 µl/min whereas in the Clark et al.10, study, 2 µl/minute was used. The flow rate between 2 and 5 µl/min is 
mainly used to mimic the physiological human aqueous humor turnover rate and it is also well documented that 
this flow rate range preserves the health of the TM in perfusion  culture17. The tissue viability data of the present 
study also supports this finding.
Figure 3.  Effect of DEX on Myocilin and Fibronectin Expression in HOCAS-TM Tissues. Representative 
confocal images of (a) myocilin and (b) fibronectin expression (green) in ETH (Vehicle)-treated (i,v), DEX-
responder (ii, vi), non-responder (iii, vii) eyes and negative control (no primary antibody) (iv, viii), DAPI 
(Blue): Nuclear counterstain. (c) Quantification of mean fluorescence intensity of myocilin and fibronectin 
expression in HOCAS-TM tissues of ETH- treated (n = 7), DEX-responder (n = 7) and non-responder eyes 
(7–9). Fluorescence images of five consecutive sections of TM from DEX treated and vehicle control eyes were 
analyzed and quantified for myocilin and fibronectin expression (green) in TM using Image J software [https ://
image j.nih.gov/ij/]. A significant increase in mean fluorescence intensity of myocilin (p = 0.0002) and fibronectin 
(p = 0.04) was found in GC responder eyes as compared to vehicle-treated eyes. Data are shown as mean ± SEM. 
*p < 0.05; ****p < 0.00001; Un-paired t test. TM-Trabecular meshwork; SC-Schlemm’s canal and CB-Ciliary body.
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DEX-treatment is known to induce the expression of several genes and proteins in the TM including 
 myocilin3. Myocilin is a glycoprotein and its physiological function is not clearly understood in the TM and 
in other ocular  tissues27. It was first identified as a major GC-responsive gene and protein in the TM and is 
also found in the aqueous humor of patients with  POAG27,28. Therefore, in the present study, the expression of 
myocilin in the HOCAS-TM tissues and its association with elevated IOP was investigated. Interestingly, our 
data revealed that a highly significant increase in myocilin expression (11.8-fold) was observed in TM region of 
the responder eyes compared to vehicle-treated eyes (p = 0.0002); and there was a fourfold increase in myocilin 
expression in GC responder eyes (p = 0.0004) compared with GC non-responder eyes. Such induction of myocilin 
upon DEX treatment was reported previously in trabecular meshwork monolayer cells and cultures of anterior 
segments, and showed the increase in myocilin expression was time and dose-dependent and correlated with the 
timing and increase of  IOP29,30. It is well accepted fact that, the induction of myocilin in response to DEX treat-
ment may not contribute to IOP raise in GC-OHT31. Recently, it is demonstrated that the induction of myocilin 
is mediated through a secondary activation of an inflammatory signaling pathway involving calcineurin and 
transcription factor  NFATC125.
Glucocorticoids are known to induce ECM changes in TM which are responsible for the aqueous outflow 
resistance in POAG. One such ECM protein is fibronectin which gets accumulated in the TM upon DEX 
 treatment29. In the present study, we also found a eightfold increase in mean fluorescence intensity of fibronectin 
expression in TM of the GC-responder eyes as compared to vehicle-treated eyes (p = 0.04; n = 7) by immunohis-
tochemical analysis. This corresponds to a previous study in perfusion cultured human eyes wherein a denser 
distribution of fibronectin was seen after DEX treatment in the JCT/inner endothelial cells of TM tissues of GC 
responder eyes as compared to control  eyes10. Very recently, an increased fibronectin and other ECM proteins 
were also found in the TM region of ex-vivo cultured human corneo-scleral segments after DEX  treatment32. 
This observation clearly supports the fact that GC responsiveness may be associated with fibronectin induction 
and ECM alterations in the TM.
It is interesting to note that, to date, 20 isoforms of fibronectin are generated in humans due to alternative 
splicing and it is not well understood how these fibronectin isoforms contributes to elevate IOP in glaucoma 
including  GIG33. The induction of fibronectin in response to GCs could be mediated through TGF-β2 and there 
are elevated levels of TGF-β2 in cultured TM cells exposed to GC treatment and in a mouse model of GC-induced 
 glaucoma30. Recent study suggested that the expression of constitutively active fibronectin-extra domain A itself 
is capable of inducing elevated IOP through TGF-β signaling in  mice34. In the present study, the levels of TGF-β2 
were not measured in perfusate of HOCAS (either by ELISA or western blotting), however, it would be worth 
investigating the relationship between TGF-β2 mediated fibronectin inductions upon DEX treatment and IOP 
response in perfusion cultured human anterior segments.
The limitations of the present study include that only limited number of paired eyes were available to assess 
the differential IOP response to DEX treatment due to high experimental rejection rate. The high experimental 
rejection rate was due to unstable baseline pressure during stabilization period. Therefore, both single eyes and 
paired eyes with stable baseline pressure were used for the present study. All the eyes used in the present study 
were from elderly donors (mean age of 73.0 ± 9.50 years) with no known ocular history. Hence, the prior history of 
GC treatment for any inflammatory conditions for the studied donors was not known. In addition, the observed 
GC sensitivity might have been greatly influenced with aged donors used in the present study.
In conclusion, this is the first study demonstrating the GC response rate in perfused human cadaveric eyes 
of Indian origin. The observed GC response rate at a 100 nM dose of DEX was similar to previously reported 
studies in perfusion cultured human eyes and clinical subjects. Increasing the DEX dose by fivefold showed 
no dose-dependent increase in GC-response rate. The known DEX-inducible proteins, such as myocilin and 
fibronectin, were found to have a positive association with elevated IOP and GC responsiveness. Thus, this study 
raises the possibility of identifying genes and proteins which are uniquely expressed by the GC responder eyes in 
the Indian population and further understanding into how these genes contribute to the differential responsive-
ness to GC therapy in all populations.
Materials and methods
Ethical statement. The donor eyes not suitable for corneal transplantation due to insufficient corneal 
endothelial cell count were included in this study. The written informed consent of the deceased donor or next 
of kin was also obtained. The study protocol was approved by the Institutional Ethics Committee of Aravind 
Medical Research Foundation (ID NO. RES2017006BAS) and was conducted in accordance with the tenets of 
the Declaration of Helsinki.
Human donor eyes. Post-mortem human eyes were obtained from the Rotary Aravind International Eye 
Bank, Aravind Eye Hospital, Madurai, India. The donor eyes were enucleated within 4 h of death (mean elapsed 
time between death and enucleation was 2.86 ± 1.18 h) and kept at 4 °C in the moist chamber until culture. All 
eyes were examined under the dissecting microscope for any gross ocular pathological changes and only eyes 
without such changes were used for the experiments. The presence or absence of glaucomatous changes in the 
study eyes were confirmed by histo-pathological analysis of the posterior segments as described earlier by our 
group (data not shown)35. The characteristics of donor eyes for this study is summarized in Supplementary 
Table S1.
DEX–induced ocular hypertension (DEX-OHT) in perfused human cadaveric eyes. Paired / sin-
gle post-mortem eyes were used to establish HOCAS by the method as described  earlier36. Briefly, human donor 
eyes were dissected out after removing vitreous, lens and iris leaving the ciliary body from the donor eyes. Then 
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the anterior segments were placed in a specially designed Petri dish with the cornea side up. The segments 
were secured with plastic O ring and perfused continuously with Dulbecco’s Modified Eagle’s Medium (DMEM, 
containing 4500 mg glucose/L, l-glutamine,  NaHCO3 and pyridoxine HCl, Sigma-Aldrich, St. Louis, MO) sup-
plemented with gentamycin (15 mg/L, Sigma-Aldrich, St. Louis, MO) and antibiotic/antimycotic solution (peni-
cillin G, 100 U/ml; streptomycin sulphate, 100 μg/ml; amphotericin B, 0.25 μg/ml: Sigma-Aldrich, St. Louis, 
MO) at a flow rate of 2.5 μl/minute using the Harvard Apparatus slow infusion pump (PHD2000, MA,USA). All 
eyes were allowed to stabilize in the HOCAS set up for at least 24–72 h. The donor eyes which failed to stabilize 
within 72 h of perfusion culture and with their outflow facility outside the range of 0.1–0.3 µl/minute/mmHg 
were excluded from the study.
After baseline stabilization, one eye of each pair or designated single eyes received 5 ml of either 100 or 
500 nM DEX at the flow rate of 200 µl/minute and the contralateral eye of the paired eyes or designated single 
eyes received 0.1% ethanol (ETH) as vehicle control and resumed the flow rate to 2.5 µl/minute with respective 
treatments until 7 days (3 doses). The eye pressure was monitored continuously using pressure transducers (APT 
300 Pressure Transducers, Harvard Apparatus, MA, USA) with data recorder (Power Lab system (AD Instru-
ments, NSW, Australia) with LabChart Pro software (ver.8.1).
Measurement of pressure change after DEX treatment. The intraocular pressure (IOP) was calcu-
lated every hour as the average of 6 values recorded every 10 min, beginning 4 h before the drug infusion and 
continued for the duration of the culture. The average IOP of 4 h before drug infusion was taken as baseline IOP 
for calculation. Mean IOP was calculated for every day (24 h) after respective treatments. Then ΔIOP was calcu-
lated using the formula: (Actual IOP averaged over 24 h—Basal IOP of individual eyes before drug treatment). 
The increase in IOP in response to DEX treatment was examined for all treated eyes. The eyes were categorized as 
GC responder (mean ΔIOP was > 5 mmHg from the baseline) and non-responder eyes (mean ΔIOP ≤ 5 mmHg 
from the baseline) after DEX treatment for 7 days as described  earlier37. The raw data of the IOP and the outflow 
facility are given in Supplementary Table S2A and 2B respectively.
Morphological analysis of the outflow tissue. At the end of the drug treatment, anterior segments 
were fixed by perfusion with 4% paraformaldehyde. Perfusion fixed anterior segments were processed for his-
tological examination using standard protocol. TM was considered normal if trabecular cells remained in their 
usual position on the lamellae (subjective assessment), and no or minor disruption of the juxtacanalicular tissue 
and trabecular lamellae were  seen32.
TUNEL staining. The effect of DEX on TM apoptosis was assessed using the terminal uridyl nick end labe-
ling (TUNEL) in  situ cell death detection kit (Roche Diagnostics GmbH, Mannheim, Germany) as per the 
manufacturer’s instructions. Briefly, the de-paraffinized sections were permeabilized with 0.2% Triton X-100 in 
0.1% sodium citrate at 4° C for 2 min and incubated with the provided fluorescein-conjugated TUNEL reaction 
mixture in a humidified chamber at 37 °C for 1 h in the dark. The TUNEL labeling solution without terminal 
transferase on tissue section was used as negative control. Tissue sections treated with DNase I served as a 
positive control. All sections were counterstained with DAPI and examined on fluorescent microscope (AXIO 
Scope A1, Zeiss, Germany) for the presence of apoptotic positive and non-apoptotic cells in the TM region of 
the anterior segments.
Immunofluorescence analysis. Immunohistochemistry was carried out as described previously with 
some  modifications20. Briefly, 5 μm tissue sections were de-paraffinized in xylene and rehydrated twice each 
with 100%, 95% and 75% for 5 min. To unmask the antigen epitopes, heat induced antigen retrieval was per-
formed with 0.1 M citrate buffer, pH 6.4 for 10 min at 95 °C and permeabilized using 0.2% Triton-X100 in PBS 
for 10  min. Tissue endogenous biotin was blocked using avidin –biotin blocking system for 10  min. Tissue 
sections were incubated with primary antibody [Myocilin (1:200), R&D Systems (cat# MAB3446), MN, USA; 
Fibronectin (1:200), Santa Cruz Biotechnology (cat# sc-52331), TX, USA, diluted in 2% BSA] overnight at 4° C 
in a humidified chamber. Sections were washed thrice with PBS and incubated with secondary antibody [anti 
mouse IgG (1:200), Santa Cruz Biotechnology (cat# sc-516142), TX, USA] for 4 h. They were then incubated 
with FITC- labelled streptavidin for 1 h, washed and mounted with anti-fade mounting media containing DAPI 
(Vector Labs, Inc. CA, USA). Images were captured using fluorescence microscope (AXIO Scope A1, Zeiss, 
Germany) or confocal microscope (Leica SP8 Confocal Microscope, Leica, Wetzlar, Germany). Tissue sections 
without primary antibody served as a negative control. Fluorescence images of five consecutive sections of TM 
from DEX treated and vehicle control eyes were analyzed for myocilin and fibronectin expression (green) in 
TM. Fluorescence images of TM was carried out for fluorescence intensity quantification using Image J software 
(National Institute of Health (NIH), Bethesda, USA) with minor  modificationsyyy38. The fluorescence intensity 
was background corrected by subtracting with average background intensity values by the formula, as “Cor-
rected Fluorescence Intensity = Fluorescence Intensity in TM—(Area of TM * Mean background fluorescence)/
Area of TM”. Five sections per tissue (Responder group, n = 7, Non-Responder group, n = 9 and vehicle treated 
group, n = 7) were analyzed. The mean fluorescence values of DEX treated group were compared with vehicle 
treated group.
Statistical analysis. Statistical analysis was carried out using Graph Pad Prism (ver.8.0.2) (Graph Pad soft-
ware, CA, USA). All data are presented as mean ± SEM or otherwise specified. Statistical significance between 
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